Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | STAT1 | P42224 | 2/20 | 0.60 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | PMM2 | O15305 | 1/20 | 0.47 |
| ▸ | MPI | P34949 | 1/20 | 0.47 |
| ▸ | PHOSPHO1 | Q8TCT1 | 1/20 | 0.47 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063191 | 0.83 | KMT2A (0.70) | POLBKMT2AMEN1MAPTMAPK1 | |
| SCHEMBL4057166 | 0.81 | KMT2A (0.63) | POLBKMT2AMEN1MAPTMAPK1 | |
| SCHEMBL1698255 | 0.79 | ALDH1A1 (0.68) | POLBKMT2AMEN1MAPTMAPK1 | |
| SCHEMBL9184563 | 0.78 | POLB (1.00) | POLBKMT2AMAPK1NPY5R | |
| SCHEMBL9229195 | 0.76 | NPSR1 (1.00) | KMT2AMEN1MAPTMAPK1ALDH1A1 | |
| SCHEMBL518604 | 0.73 | KMT2A (0.67) | POLBKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL4504593 | 0.72 | POLB (1.00) | POLBKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL4018661 | 0.72 | POLB (0.70) | POLBKMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL6319271 | 0.71 | PKM (0.66) | POLBKMT2AMAPTALDH1A1LMNA | |
| SCHEMBL14518042 | 0.71 | ALDH1A1 (0.59) | POLBMAPK1ALDH1A1LMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | claimed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | claimed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | POLB 2936/4885KMT2A 1216/4885MEN1 4495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.